Oct 20, 2021 / 05:30PM GMT
Robert Burns - H.C. Wainwright & Co. - Analyst
For our next fireside chat, I am joined by Dr. Kris Vaddi, the CEO of Prelude Therapeutics. Dr. Vaddi, thank you for joining us today.
Kris Vaddi - Prelude Therapeutics Inc. - CEO
Thank you. Thank you for the invitation to join.
Questions and Answers:
Robert Burns - H.C. Wainwright & Co. - AnalystWell, I certainly look forward to a lively discussion especially with all the data sets that were recently released at the triple meeting. But before we get into the pipeline and all the data that was released, for those who may be new to the Prelude story, can you provide a brief high-level overview of Prelude's discovery and development approach, as well as the pipeline that you've developed around that approach?
Kris Vaddi - Prelude Therapeutics Inc. - CEO
Yes, absolutely. For those of you who are new to Prelude's story, we are recently public. About a year ago, we went public, but we are a five-year-old company that
Trustpilot
